Evogene Ltd. Stock TEL AVIV STOCK EXCHANGE
Equities
EVGN
IL0011050551
Biotechnology & Medical Research
Sales 2024 * | 17M 64.61M | Sales 2025 * | 31.5M 120M | Capitalization | 32.16M 122M |
---|---|---|---|---|---|
Net income 2024 * | -20M -76.01M | Net income 2025 * | -17M -64.61M | EV / Sales 2024 * | 1.89 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 1.02 x |
P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.27% |
Latest transcript on Evogene Ltd.
Managers | Title | Age | Since |
---|---|---|---|
Ofer Haviv
CEO | Chief Executive Officer | 58 | 01-12-31 |
Yaron Eldad
DFI | Director of Finance/CFO | 57 | 22-03-31 |
Mark Kapel
CTO | Chief Tech/Sci/R&D Officer | 48 | 04-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Dan Falk
BRD | Director/Board Member | 79 | 21-11-16 |
Sarit Firon
CHM | Chairman | 58 | 16-08-10 |
Leon Recanati
BRD | Director/Board Member | 76 | 05-04-30 |
1st Jan change | Capi. | |
---|---|---|
-1.82% | 41.36B | |
+44.25% | 41.3B | |
+2.56% | 39.61B | |
-12.11% | 25.62B | |
+3.09% | 24.09B | |
-24.16% | 18.38B | |
+22.12% | 11.85B | |
-3.74% | 11.82B | |
+7.75% | 11.07B |